• White House targets xylazine

    The Biden administration released a plan July 11 to clamp down on xylazine-fentanyl mixtures, a drug combination that it labeled an emerging threat in April and that has mystified clinicians.
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • 'Advocate for yourself,' Encompass pharmacy leader tells others with disabilities

    When an illness paralyzed Renee Tyree, PharmD, at 19 years old, she was told she wouldn't become a doctor after she became a wheelchair user. 
  • ASHP names 6 hospital pharmacies as centers of excellence

    The American Society of Health-System Pharmacists has honored six hospitals with its certificate of excellence in medication use safety and pharmacy practice.
  • FDA OKs more cisplatin drug imports

    The FDA is allowing 10 more lots of cisplatin from a China-based pharmaceutical company to be imported to the U.S. to ease the ongoing cancer drug shortage, Bloomberg reported July 10. The additional lots are set to arrive next week. 
  • Prehospital pediatric dosing is wrong 57% of the time: Study

    Nearly six in 10 children who take medicine for an out-of-hospital emergency are given the incorrect dosage, according to a study published July 10 in Pediatrics. 
  • CVS-owned pharma company to lay off 195 workers

    Heartland Healthcare Services, a pharmacy company owned by CVS Health and HCR-ManorCare, plans to close two facilities and lay off 195 workers in Ohio and Maryland, according to WARN filings. 
  • Intermountain rolls out birth control access form after revision to Utah law

    A recent revision to a Utah law allows pharmacists in the state to prescribe birth control to patients without a physician-issued order. And Salt Lake City-based Intermountain Health wasted no time implementing a new program to carry this out. 
  • 138 drugs in shortage: FDA

    The U.S. is low on about 140 drugs, including critical cancer therapies and local anesthetics, according to the FDA's drug shortage database. 
  • Viewpoint: Effects of 'essential' drug shortages on hospital patient care 

    In the first quarter of 2023, 301 "basic hospital drugs" were in short supply across the United States, causing treatment delays and increasing the chance of medication errors, according to a July 7 American Hospital Association letter to members of Congress.
  • Cipla recalls 6 batches of albuterol

    Warren, N.J.-based Cipla USA, a subsidiary of India-based pharmaceutical company Cipla, recalled six batches of albuterol sulfate inhalation aerosol solutions after one complaint of the product leaking. 
  • Hawaii hospital invests $2.3M into pharmacy expansion

    Kealakekua, Hawaii-based Kona Community Hospital hosted a groundbreaking for its pharmacy expansion project, which cost $2.3 million and includes a clean room suite, Big Island Now reported July 6. 
  • FDA fully approves Alzheimer's drug Leqembi

    The FDA granted full approval to Leqembi (lecanemab) July 6, six months after handing Eisai and Biogen's Alzheimer's drug an accelerated approval. 
  • Keck Medicine taps chief pharmacy officer

    Keck Medicine of USC, based in Los Angeles, promoted Krist Azizian, PharmD, to fill the systemwide role of chief pharmacy officer. 
  • Lung cancer drug candidate fails to meet primary endpoint in phase 3

    In a phase 3 trial, an investigational cancer drug from AstraZeneca and Daiichi Sankyo did not improve overall survival rates, and some patients died during the study, the organizations said July 3. 
  • Astellas to withhold prostate cancer drug from contract pharmacies

    Astellas Pharma US will stop distributing Xtandi, a prostate cancer drug that costs about $160,000 each year, to 340B contract pharmacies on Sept. 1, according to a letter obtained by 340B Health. 
  • FDA rejects Amneal's Parkinson's drug

    The FDA has rejected Amneal Pharmaceuticals' new drug application for IPX203, which the company hoped would be approved for treatment of Parkinson's disease.
  • Dartmouth employs 3 pharmacy robots

    Three pharmacy TUG robots will debut at Lebanon, N.H.-based Dartmouth Health's Hitchcock Medical Center this summer.
  • FDA approves 1st gene therapy for hemophilia A

    The FDA approved the first gene therapy treatment for adults with severe hemophilia A.
  • Leiters rebrands to focus on expansion

    Leiters, an FDA registered provider of sterile pharmacy services based in Englewood, Colo., announced the company's rebranding to Leiters Health to focus on expanding in the healthcare market.
  • Trial for 1st fully AI-generated drug underway

    Insilico Medicine, a biotech company based in Hong Kong, created the first drug generated entirely by artificial intelligence to successfully reach clinical testing on humans, CNBC reported June 29.

Featured Whitepapers

Featured Webinars